Application
Antibodies tested include p-4E-BP1/2/3 (Thr 45): (A, B, C) and 4E-BP1 (R-113): (D, E, F).Application
Western blot analysis of 4E-BP1 phosphorylation in non-transfected: (A), untreated human 4E-BP1 transfected: (B) and lambda protein phosphatase treated human 4E-BP1 transfected: (C) 293T whole cell lysates.Application
Western blot analysis of phosphorylated 4E-BP1/2/3 expression in untreated (A) and EGF-treated (B) MDA-MB-435 whole cell lysates.Application
Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast carcinoma tissue showing nuclear and cytoplasmic localization.| Product Name | p-4E-BP1/2/3 Antibody (Thr 45) |
|---|---|
| Antibody Type | Primary Antibodies |
| Modification Notes | The multisubunit eukaryotic translation initiation factor (eIF) 4F recruits 40S ribosomal subunits to the 5' end of mRNA. The eIF4F subunit eIF4E interacts directly with the mRNA 5' cap structure. Assembly of the eIF4F complex is inhibited by a family of repressor polypeptides, the eIF4E-binding proteins (4E-BPs). 4E-BP1 (also known as PHAS-1) normally binds eIF4E, inhibiting cap-dependent translation. Hyper-phosphorylation of 4E-BP1 disrupts this binding, activating cap-dependent translation. The PI3-kinase/Akt pathway and the FRAP/mTOR kinase regulate 4E-BP1. 4E-BP1 is phosphorylated in vivo on multiple residues and phosphorylation by FRAP/mTOR on Threonine 37 and Threonine 46 of human 4E-BP1 may prime it for sub-sequent phosphorylation at sites including Serine 65 and Threonine 70. The corresponding rat residues include Threonine 36, Threonine 45, Serine 64 and Threonine 69. In vitro, 4E-BP1 is also phosphorylated by ataxia telangiectasia (ATM) at human Serine 112 (rat Serine 111) in response to an increase in insulin levels. |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | WBIPIFIHC |
| recommended for detection of Thr 45 phosphorylated 4E-BP1/2/3 of human origin and correspondingly phosphorylated Thr 44 of mouse and rat origin by WB, IP, IF and IHC(P) | |
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml |
| Purification | Affinity purified |
| Alternative Names | epitope corresponding to phosphorylated Thr 45 of 4E-BP1/2/3 of human origin |
|---|---|
| Tissue Specificity | epitope corresponding to phosphorylated Thr 45 of 4E-BP1/2/3 of human origin |
| Entrez Gene | 1978 |
|---|
Application
Antibodies tested include p-4E-BP1/2/3 (Thr 45): (A, B, C) and 4E-BP1 (R-113): (D, E, F).
Application
Western blot analysis of 4E-BP1 phosphorylation in non-transfected: (A), untreated human 4E-BP1 transfected: (B) and lambda protein phosphatase treated human 4E-BP1 transfected: (C) 293T whole cell lysates.
Application
Western blot analysis of phosphorylated 4E-BP1/2/3 expression in untreated (A) and EGF-treated (B) MDA-MB-435 whole cell lysates.
Application
Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast carcinoma tissue showing nuclear and cytoplasmic localization.| Application Notes | recommended for detection of Thr 45 phosphorylated 4E-BP1/2/3 of human origin and correspondingly phosphorylated Thr 44 of mouse and rat origin by WB, IP, IF and IHC(P) |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
